---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-240645"
form_type: "8-K"
ticker: "JAGX"
cik: "0001585608"
company_name: "Jaguar Health, Inc."
filed_at: "2026-05-27T13:10:06+00:00"
generated_at: "2026-05-27T13:14:00.035938+00:00"
event_type: "regulatory"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Jaguar Health regains Nasdaq Bid Price compliance; monitoring until May 2027

## Summary
- Formal notice from Nasdaq on May 26, 2026: Jaguar complies with Bid Price Rule (closing bid ≥$1/sh).
- Panel maintains jurisdiction until Sept 1, 2026; Mandatory Panel Monitor imposed until May 26, 2027.
- If bid price <$1 for 30 consecutive trading days during monitoring, no 180-day grace period; delisting possible.
- CEO Lisa Conte reported Q1 2026 net revenue +816% YoY and +527% QoQ, driven by out-license with Future Pak.
- Company targets NDA for crofelemer formulation in mid-2027 and seeks development/commercialization partner.

## SEC filing metadata
- accession: 0001193125-26-240645
- form_type: 8-K
- ticker: JAGX
- cik: 0001585608
- company_name: Jaguar Health, Inc.
- filed_at: 2026-05-27T13:10:06+00:00
- event_type: regulatory
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1585608/000119312526240645/0001193125-26-240645-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1585608/000119312526240645/d129501d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-240645
- JSON: https://secwatch.observer/filing/0001193125-26-240645.json
- Plain text: https://secwatch.observer/filing/0001193125-26-240645.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.